

Please amend the above-referenced application as follows:

In the Specification:

Please amend the disclosure on page 1 to read:

This application is a continuation application of serial no. 08/599,226, filed on February 9, 1996, issued as Patent No. 6,090,382. The contents of all of the aforementioned application(s) are hereby incorporated by reference.

In the Claims:

Please cancel claims 72, 74, 75, and 82 without prejudice.

Please amend the claims as follows (for convenience all of the claims, whether amended or not, are presented below):

65. A method for inhibiting human TNF $\alpha$  activity comprising contacting human TNF $\alpha$  with an antibody such that human TNF $\alpha$  activity is inhibited, wherein the antibody is an isolated human antibody, or an antigen-binding portion thereof, that dissociates from human TNF $\alpha$  with a  $K_d$  of  $1 \times 10^{-8}$  M or less and a  $K_{off}$  rate constant of  $1 \times 10^{-3}$  s $^{-1}$  or less, both determined by surface plasmon resonance, and neutralizes human TNF $\alpha$  cytotoxicity in a standard *in vitro* L929 assay with an  $IC_{50}$  of  $1 \times 10^{-7}$  M or less.

66. A method for inhibiting human TNF $\alpha$  activity comprising contacting human TNF $\alpha$  with an antibody such that human TNF $\alpha$  activity is inhibited, wherein the antibody is an isolated human antibody, or antigen-binding portion thereof, with the following characteristics:

a) dissociates from human TNF $\alpha$  with a  $K_{off}$  rate constant of  $1 \times 10^{-3}$  s $^{-1}$  or less, as determined by surface plasmon resonance;

62